Vertex Agrees to Pay Over $10 Billion for Crinetics Pharmaceuticals at a Premium
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a deal valued at over $10 billion, paying more than double the latter's current valuation. The acquisition is driven by Vertex’s interest in Crinetics' drug candidate Atumelnant, which shows promise for treating congenital adrenal hyperplasia.
Topics: healthcare M&A pharmaceuticals